有人说,兆科眼科是被低估的眼科创新药公司。 一方面,今年兆科眼科将进入临床药物的收获期,对于创新药企而言,产品获批上市就意味着有了造血能力,会有更多资金投入到研发中。另一方面,在今年创新药的“牛市”行情下,兆科眼科年内涨幅约140%。虽涨幅亮眼,但兆科眼科的市净率还不到1,这是否说明公司目前的市值还是被大幅低估了? 兆科眼科身后有着GIC(新加坡政府投资公司)、高瓴资本等明星创投,公司在二级...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.